<PAGE> 1
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the year ended December 31, 1998
ZAXIS INTERNATIONAL INC.
(Name of Small Business Issuer in Its Charter)
Delaware 0-15476 68-0080601
(State of Incorporation) (Commission (IRS Employer Identification No.)
File Number)
1890 Georgetown Road, Hudson, Ohio 44236
(Address of principal executive office)
(330) 650-0444
(Issuer's telephone number, including area code)
Securities registered under Section 12(b) of the Exchange Act: None.
Securities registered under Section 12(g) of the Exchange Act: Common Stock,
$.01 par value.
Check whether the registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months and (2) has
been subject to such filings for the past 90 days. Yes[X] No[ ]
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained, to
the best of Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. [X]
Issuer's net sales for its most recent fiscal year: $188,732
The aggregate market value of the voting stock held by non-affiliates was
$1,259,360 based on the average of the bid and asked prices on March 31, 1999
($.43). Officers and directors are considered affiliates for purposes of this
calculation. The bid and asked prices are based on a small volume of infrequent
trading in the stock.
As of March 31, 1999, there were 5,858,106 shares of common stock outstanding.
Transitional Small Business Disclosure Format. Yes[ ] No[X]
DOCUMENTS INCORPORATED BY REFERENCE:
Portions of Issuer's definitive proxy statement for its 1999 Annual Meeting of
Stockholders, which the Issuer will file, are incorporated by reference into
Part III.
Page 1 of 22 pages. Exhibit index is located on page 10.
<PAGE> 2
PART 1
ITEM 1. DESCRIPTION OF BUSINESS.
BUSINESS DEVELOPMENT
Zaxis International Inc. ("International") is a holding company which operates
its business through its wholly-owned subsidiary, Zaxis Inc. ("Zaxis"). Zaxis
was incorporated in Ohio in 1989. On August 25, 1995, Zaxis merged with a
subsidiary of The InFerGene Company ("InFerGene") and InFerGene changed its name
to Zaxis International Inc. For accounting and tax purposes, the merger was
treated as a reverse acquisition in which Zaxis acquired International.
InFerGene and its subsidiary were inactive and had no assets or liabilities at
the time of the merger. InFerGene was incorporated in California in 1984 and
subsequently chartered in Delaware in 1985.
Zaxis was founded by Raymond Gesinski, Ph.D., (deceased), and Gregory Bambeck,
Ph.D., Director of Research, to develop products for use in life sciences
research. Each had backgrounds in genetic research, cardiovascular diagnostic
developments, and polymer technology in gene separation applications. In 1994
and 1995, Zaxis implemented a program to develop, manufacture and market a
complete product line based on the research of Drs. Gesinski and Bambeck and to
continue research and development of related products. During that period, the
Company moved into new manufacturing and office facilities, installed automated
and computer controlled production equipment, prepared its lipoprotein testing
system for FDA approval, and began establishing marketing arrangements with
domestic and foreign distributors. A private placement of common stock and
warrants to purchase common stock was completed in the third quarter of 1995,
adding capital funds of $1.4 million. In 1996, holders exercised 465,743 Class A
Warrants, providing $1,048,000 in additional capital funds and International
sold approximately $605,000 in notes with warrants attached in private sales.
With the Company stalled in 1997, new investors and new management became
contributors to the Company. Investment sources in Australia took an active role
in funding Zaxis. Subsequently the various Australian sources have invested
$1,458,907 to the further development of Zaxis. At a fully diluted position, one
Australian entity, Progen Industries Ltd., would hold about seventeen percent of
the Company and would be the largest single shareholder. Currently, Progen
ownership of issued shares is 6%. Company ownership is internationally and
broadly based, with about 2,500 shareholders worldwide. Concurrent with the
infusion of Australian funds, the Board of Directors was structured with five
active members, and those five Directors continue to serve the Company and have
been recommended to the shareholders for election to serve during the next
ensuing term. Management under the era of Australian-led investments has been
stable, with the current chairman in that position for more than two years, and
the chairman holding the additional role of president for two years. The
financing stability provided by the Australian group, with three members on the
five-member board, has provided a foundation for additional investments by
long-term shareholders of the Company, particularly from the Northeast Ohio and
Florida areas. The relationship between the Australian groups and original
investors has been cooperative. The Company has in this period been able to
reformulate the platform product, the protein gel, and to bring the
forward-looking DNA gel to marketability.
Fundings for the Company in 1997 and 1998 have been predominately in convertible
note instruments. In 1998, renewals and new notes issued under 9 1/2%
Convertible Note offerings totaled $831,317. In 1997 renewals and new notes
issued under 10% and 9 1/2% Convertible Note offerings totaled $1,213,879. Also
in 1997, equity capital in the amount of $170,000 was provided through issuance
of common stock, and $391,410 of the convertible notes subscribed in 1996 were
converted to common stock.
2
<PAGE> 3
BUSINESS OF ISSUER
Zaxis manufactures and sells products used in an electrochemical process known
as electrophoresis which is used in more than 55,000 laboratories world wide in
applications for the separation and identification of genes (e.g., DNA) and gene
products (e.g., RNA, proteins). A variety of techniques, formats, materials,
compounds, equipment and devices are employed in electrophoresis, and Zaxis'
catalog includes products for virtually all of these needs. Zaxis' research and
marketing direction is focused on the consumables segment of the electrophoresis
market, predominately on pre-cast gels.
Electrophoresis was discovered in the 1930s and has been in growing usage for
more than fifty years. It has been reported that eighty percent of all
life-science researchers in the United States use electrophoresis as a lab tool.
Laboratory applications cover a broad spectrum, including medical diagnostics,
immunology, agriculture, criminology, forensics, pharmaceuticals, quality
assurance and DNA and RNA research. A simplified explanation of the process
describes it as the application of molecularly disassembled specimens, such as
bacteria, blood serum, body tissue or plant tissue, to a gel substance which is
then subjected to electric current while submerged in a liquid filled chamber.
The sample material molecules are deposited on the gel substance in a unique
pattern which can be compared to other samples to determine similarities or
differences. The pattern of molecules is popularly referred to as a "bar code"
of living matter.
The usefulness of the information from electrophoresis depends on the clarity
and consistency of the results (or resolution) which is dependent upon a variety
of factors, including consistency of manufacturing materials and methods for the
devices, chemicals and gels. Gels can be compounded and polymerized in the end
user's laboratory by technicians or supplied in pre-cast form in plastic or
glass cassettes. Generally, gels are made from one of two materials: a natural
plant-based substance called agarose or an acrylamide-based substance. Agarose
gels are generally limited to use with proteins of larger molecular size.
Polyacrylamide gels are available in mass-produced pre-cast cassettes or may be
prepared one at a time by hand by the technician from compounds or premixed
preparations. The pre-cast cassette offers the advantages of convenience,
efficiency, consistency, and reliability and are being used by a growing number
of users.
Zaxis' core product is a pre-cast polyacrylamide gel cassette based upon its
in-house research utilizing proprietary polymer chain length control ("PCL")
technology. The gel cassettes can be used with Zaxis' proprietary
electrophoresis devices or with devices of other manufacturers. Zaxis' product
line includes electrophoresis systems and components, chemicals, compounds,
stains, reagents, chambers, power supplies, computers, scanners, and accessories
in addition to gel cassettes. The gel cassettes, chemical compounds and many of
the acrylic components are manufactured or assembled by Zaxis in its facility,
while the microprocessor components, scanners, power supplies and other system
components are manufactured to Zaxis' specifications by other companies.
In its initial pre-cast gel product line introduction in 1995, the Company was
not able to gain any significant market share due to production quality
variances and a novel application method proprietary to Zaxis' products, which
was thought to be a selling advantage, but proved not to be. In 1997, under the
direction of the new management team, the polyacrylamide product line was
removed from market except for continued shipments to existing customers, and an
extensive re-design of the product was undertaken. An advanced formulation of
the basic product line was introduced to Beta-site testing in December 1997.
Test-user responses in 1998 were positive, and the advanced product line of
protein gels were placed in the market place in the last half of 1998. All of
the Company's existing distribution sources for the product have accepted the
re-designed product into their inventory to replace the prior version. Based on
the re-designed product line,
3
<PAGE> 4
discussions are being conducted with additional potential distributors for the
line. A major supply contract has been negotiated with one of the key supply
companies in the bio-technology arena. The contract was signed March 5, 1999,
after 18 months of negotiations, extensive product testing by the customer and
due-diligent visits to the Zaxis manufacturing facility. The product will be
marketed under the established name of the customer. Sales are expected to begin
in the second quarter of 1999.
Zaxis developed and sells a lipoprotein assay system, consisting of a
poly-gradient electrophoresis gel, electrophoresis processing equipment,
reagents, gel scanner, computer software and hardware. The system measures the
relative percentages of High Density and Low Density Lipoproteins (HDL and LDL)
in human blood serum in a single test from single samples. Within the general
categories of HDL and LDL are subfractions variously designated as Very Low
Density Lipoprotein, LDL 1 and 2 and HDL 1, 2 and 3. The Zaxis system obtains
its measurement by separating the subfractions and then programatically
computing the totals of the components, rather than simply measuring the two
masses of LDL and HDL, as competing systems do. The system was granted FDA
marketing approval in September 1996 on the basis that it provided measurements
in terms of total LDL and HDL equivalent to other systems already approved. The
lipoprotein subfractions measurements unique to the Zaxis system were not part
of the FDA clearance for clinical marketing purposes, but are the subject of
ongoing research by the Zaxis research and development staff and by outside
researchers who have purchased the Zaxis system. In December 1996, the Company
was granted a patent for the poly-gradient gel component of the system.
The Company has been marketing the lipoprotein assay system to researchers since
March 1996. In late 1996, the Company began selling lipoprotein gels and reagent
kits separately to researchers who had not purchased the systems. The Company
has not actively pursued the clinical market yet because it does not currently
possess the staff and marketing resources to do so. Sales of the system and
supplies of lipoprotein gels for use in the system continue to be made to
researchers who learn of the product from other researchers. In 1998, three LFS
systems were sold worldwide, one each in Germany, Malaysia, and the United
States; each are now in operation, and usage is driving continuing purchases of
the consumable LFS gel from Zaxis. One medical center acquired the system to use
the Zaxis test as a central source of data for an arterial cardiovascular
battery of tests. The test series was developed "to provide physicians and
patients with the information necessary to maximally reduce the progression of
atherosclerotic disease," as was stated in the announcement of the program in
April 1999. Zaxis is following the results of the introduction very closely.
The Company has successfully designed and produced a long-life, full-sized
pre-cast gel for use in DNA sequencing and during 1997 and 1998 received
satisfactory reports on prototype gels placed for Beta-testing with several
companies that manufacture or market DNA sequencing instruments and supplies.
During 1998 the company engineered several adapter apparatus that enable the
Zaxis DNA gel to be run on the major models of manual DNA sequencers now in
operation. Based on the performance of the new product line, discussions are
being conducted with potential distributors for the line. The Company believes
that, at this time, its pre-cast DNA sequencing gel will be the only marketed
full-sized gel to meet all the parameters required by researchers and to fulfill
specifications needed in the DNA sequencing market.
SUPPLIERS
The raw materials and system components that Zaxis uses in its products are
readily available from multiple reliable sources.
4
<PAGE> 5
CUSTOMERS AND DISTRIBUTION METHODS
Six customers accounted for 55% of sales and ten customers accounted for 73% of
sales in 1998. Two customers accounted for 58% of sales in 1997. The four
largest customers in 1998 were OEM accounts. Five of the ten largest customers
sell or acquire for their own use Zaxis products under the Zaxis brand label.
The Company sells directly to research, educational and medical institutions
under the Zaxis brand.
PATENTS, TRADEMARKS, AGREEMENTS
In addition to the December 1996 patent on the poly-gradient gel, the Company
has patents on its electrophoresis device, a cassette and a cassette component.
The Company has three patent- applications pending, including one on the DNA
product. The Company has U.S. trademarks covering "Zaxis - A New Dimension In
Technology," "Z-Quence" and the term "Z-Gel." Zaxis has a trademark application
pending for the marketing phrase, "Bio Tools for Technology." In addition, Zaxis
relies on trade secrets and proprietary knowledge. There can be no assurance
that patents or trademarks will not be challenged or breached or that
confidentiality agreements will not be breached.
Zaxis provides proprietary software for its Lipoprotein Fractionation System,
LFS, and grants limited, non-exclusive rights to the use of the software by its
customers who purchase the Lipoprotein Fractionation System.
GOVERNMENTAL REGULATIONS
The Zaxis manufacturing plant is a registered FDA facility and is subject to FDA
regulation, including audit and review for compliance with agency rules. The
Company believes it is in compliance with the FDA regulations. The facility has
not been audited and the Company has not received notice of any planned or
pending audits. As a result of the award of a Governmental Services Agency
contract, which became effective April 1, 1998, the Company is subject to
routine audits of GSA vendors.
RESEARCH AND DEVELOPMENT
Research and development costs were approximately $241,777 in 1998 and $126,940
in 1997. None of the expenses were borne by customers. The increase reflected
the extensive re-design of the protein gel and the completion of research on the
DNA gel.
ENVIRONMENTAL LAWS
Zaxis has not incurred any costs specifically for compliance with environmental
laws and does not anticipate any material costs solely for this purpose. The
Company is subject to routine hazardous materials handling rules of the
Environmental Protection Agency, if and when such materials are employed in a
manufacturing process.
EMPLOYEES
Zaxis has 13 full time employees. In addition, the Company utilizes outside
consultants and several full-time workers on a contract basis.
The Company believes it has good relations with its employees and has
experienced no strikes or work stoppages.
5
<PAGE> 6
ITEM 2. DESCRIPTION OF PROPERTY.
Zaxis' operations are conducted in a facility consisting of a 19,800-square-foot
building in Hudson, Ohio, which is rented under a lease that expired October 31,
1998, and was renewed to October 31, 2003. The building is approximately eight
years old, is in good condition and is sufficient for currently anticipated
needs of the Company for at least three years. In 1998, the building was offered
to the Company by an agent for the owner, and Zaxis entered into a purchase
agreement, but the Company was unable to secure necessary funding through a
preliminary commitment that was withdrawn after the credit market contractions
in September 1998.
ITEM 3. LEGAL PROCEEDINGS.
None other than routine litigation incidental to the business.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
No matters were submitted to a vote of security holders during the fourth
quarter of 1998.
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.
There is no established public trading market at present in the United States or
elsewhere for International's common stock. Over-the-counter trading volume is
reported by NASD through its "Bulletin Board" system. Trading was moderate
during 1998. There were about 2,500 holders of record of International common
stock at the end of the first quarter 1999, including holders of InFerGene and
Zaxis shares who have yet to exchange their shares for International shares. No
cash dividends have been declared on the common stock and none are currently
anticipated. The high and low bid prices quoted for each quarter during the last
two fiscal years are presented below. The quotations reflect inter-dealer
prices, without retail mark-up, mark-down or commission and may not represent
actual transactions.
<TABLE>
<CAPTION>
Quarter Ended High Low
------------- ---- ---
<S> <C> <C>
March 31, 1997 3.25 1.50
June 30, 1997 1.75 1.375
September 30, 1997 2.00 1.50
December 31, 1997 1.875 0.56
March 31, 1998 0.625 0.5625
June 30, 1998 0.78 0.75
September 30, 1998 0.625 0.50
December 31, 1998 0.343 0.29
March 31, 1999 0.437 0.375
</TABLE>
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS.
RESULTS OF OPERATIONS
Net sales were $188,732 in 1998, down $85,807 from $274,539 in 1997, or 31%
percent from 1997. Due to the withdrawal of the pre-cast protein gel line from
the market in 1997, as discussed
6
<PAGE> 7
in Item 1, Business of the Issuer, no new distribution sources were developed in
1997 or 1998, and sales through existing distribution sources were reduced. The
private label protein contract referred to in "Business of Issuer" was
negotiated in 1998 and is expected to generate initial sales in the second
quarter of 1999. The first end-user sale of the DNA Sequencing pre-cast gel
occurred in January 1999 at a testing-quantity level.
Cost of goods sold exceeded sales in both 1998 and 1997. In March of 1997, the
Company took delivery on a custom-designed automated product packaging system
for protein gels. In addition, the Company incurred significant additional costs
through a regimented in-house product-testing protocol designed to perfect the
re-designed protein gel before it was offered for sale or even offered to
Beta-site testers.
Total operating expenses after cost of goods sold were increased by $107,849 or
13% to $923,715 from $815,866, all due to increased costs in research and
development. General and Administrative expenses were $510,786 in 1998 and
$517,992 in 1997. Selling expenses were $171,153 in 1998 compared to $170,934 in
1997. Research and Development expenses increased by $114,837, or 90%, to
$241,777 in 1998 compared to $126,940 in 1997. This was due to extensive in
house testing before release of reformulated gels to the market.
FINANCIAL CONDITION AND LIQUIDITY
The Company used $828,153 in operations in 1998 compared with $992,009 in 1997,
and $9,812 for equipment and patent expenditures in 1998 compared with $31,834
in 1997. Proceeds from notes payable (mainly notes with common stock warrants)
of $831,317 provided the cash for these uses. At December 31, 1998, current
liabilities exceeded current assets by $2,039,728, and total liabilities
exceeded total assets by $2,607,733. The Company is reliant upon investors to
provide funds for operations and is working to maintain in 1999 steady relations
with creditors while it strives to improve sales volume and demonstrate that the
Company can be successful.
To achieve this, the Company in 1997 and 1998 re-designed its core market-entry
product, the pre-cast polyacrylamide protein gel, as discussed above, and
completed research and development on its long-shelf-life, pre-cast DNA
sequencing gel. The Company also continues to acquire additional research
customers for its lipoprotein assay system or components at a slow,
word-of-mouth rate.
Management believes that the core product and the DNA sequencing product can
provide sufficient sales revenue to bring the Company to profitability if
additional contracts can be negotiated during 1999. Management also believes
that the lipoprotein assay system represents a significant technological
improvement over existing cardiac disease diagnostic systems and can be a
profitable future source of revenues. There can be no assurance, however, that
the Company will be successful in obtaining more necessary contracts and
commitments from distributors and potential partners to achieve profitable
operations. If the Company is successful in obtaining the necessary contracts,
then the Company will require additional capital investment for production
capacity and additional production staff.
During 1998, the Company relied upon investor financing to sustain on-going
operations, research and development. Sources of these investments were largely
directors of the corporation, and their affiliated business interests, and prior
investors who made additional commitments of funds through two-year convertible
notes. The Company continues to rely upon these sources of funding. Discussions
have been conducted with potential new investors for long-term debt or equity
funding, but to date no transaction has been completed. The Company will
necessarily be reliant
7
<PAGE> 8
upon such sources of funding until the marketing of the principal products can
be brought to a level sufficient to support the operating requirements of the
Company. There can be no assurance that the Company will continue to receive
investor funding nor that the Company will be able to strengthen its customer
base sufficiently to generate sales volume required to meet or exceed the costs
of operations.
YEAR 2000 TECHNOLOGY
The Company expects that Year 2000 technology problems occurring from dating
issues, if any occur, will be externally driven rather than internally driven.
The most date-sensitive system operated by the Company is the accounting
program, a version of Solomon. The Company anticipates that it will need to
replace its Solomon accounting software program, though it has been told by
Solomon that the version in use at Zaxis is Y2K compliant in all modules. The
Company conducted its own test of the Solomon program, with an 01/01/00 date,
and the program did not read the date correctly, thus the expectation that the
program will have to be replaced. Some software utilized by the Company for
other routine business functions could require the purchase of upgrades in some
instances, though most programs are current in the versions utilized. For
example, the Company operates on Windows 95 with Office Suite 97 as the platform
for word processing, spreadsheets, and databases, and Lotus Notes is used for
certain production records. A proprietary program provided by the Company for
use in the analysis program for the LFS gels may require some programming
modifications; the costing of this has been determined and is included in the
Company's Y2K projection of required expenditures. All regular suppliers have
been contacted for a Y2K compliance assurance; most have responded with
affirmation, representing about 85 percent of the purchased goods of the
Company. Those not yet responding are being contacted individually, but none
represent single-source supply lines.
In terms of readiness for externally controlled events, department managers have
made the following assessments: The Company is dependent on public utilities,
including gas, electric, water and waste disposal. The Company can provide for a
back-up water supply of 3,375 gallons, which would provide for 60 calendar days
of manufacturing operations. A decision on whether connecting the alternate
water storage system is necessary will be made by November 1, 1999, and
implemented by the end of that month if believed necessary. The Company could
operate without gas except in extreme winter cold, as gas is the source for
heating, by utilizing electric space heaters. The Company will make a decision
on whether back-up heat is required by October 1, 1999, and complete
implementation by the end of that month if believed necessary. In case of
electrical power outage, operation will have to be suspended. To protect product
and critical samples, the deep freeze trunk and walk-in cooler can be powered
with a gasoline generator at a cost of $1,500. Potentially, electrical outages
would close the company. Sanitary waste disposal can be arranged with portable
units. The company will make a decision on whether back-up sanitation is
required by August 1, 1999, and will complete implementation by October 1, 1999,
if believed necessary. It is not anticipated that any vital supply sources will
be unable to supply, assuming freight transportation is operating; the company
will stock 60-day levels of essential supplies by December 15, 1999. All
employees live at distances beyond walking or cycling commutes, and should
gasoline or other automotive services be hindered, the Company could be
disrupted or even severely impacted by the inability of employees to travel to
the plant for work schedules.
The Company has projected expenditures for Y2K-related upgrades and alternative
programs to be: accounting program upgrade or replacement, $30,000: other
software upgrades $5,000; proprietary software alterations, $2,500; computer
hardware replacements, $10,800; computer hardware upgrades, $5,000; water
storage system hookup, $2000; all for a total budget estimate of $55,300.
Sources were contacted in the first quarter 1999 and vendor estimates are being
received during the second quarter. No expenditures have been made to date since
the Company intends to make
8
<PAGE> 9
application for Small Business Administration funding for the Y2K fixes under
provisions of the "Small Business Year 2000 Readiness Act of 1999."
ITEM 7. FINANCIAL STATEMENTS.
Financial statements of the Registrant and the reports of independent auditors
thereon are included on the following pages.
<TABLE>
<CAPTION>
Pages
-----
<S> <C>
Reports of Independent Auditors 12
Balance Sheets 13
Statements of Operations 14
Statement of Changes in Stockholders' Equity 15
Statements of Cash Flows 16
Notes to Financial Statements 17-23
</TABLE>
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None. At the 1998 Shareholder meeting, shareholders affirmed the re-appointment
of Ernst & Young L.P. as auditors for the year ended December 31, 1998.
PART III
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS,
COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT
The information required by this item is incorporated by reference from the
Registrant's definitive proxy statement that will be filed as an amendment to
this Form 10-KSB under cover of Form 8.
ITEM 10. EXECUTIVE COMPENSATION
The information required by this item is incorporated by reference from the
Registrant's definitive proxy statement that will be filed as an amendment to
this Form 10-KSB under cover of Form 8.
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this item is incorporated by reference from the
Registrant's definitive proxy statement that will be filed as an amendment to
this Form 10-KSB under cover of Form 8.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this item is incorporated by reference from the
Registrant's definitive proxy statement that will be filed as an amendment to
this Form 10-KSB under cover of Form 8.
9
<PAGE> 10
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Exhibit
Number Description
- ------ -----------
3(i) Certificate of Incorporation (Exhibit 3(i) to the Company's
Annual Report on Form 10-KSB for the year ended December 31,
1995, File Number 0-15476, incorporated herein by reference).
3(ii) By-laws Certificate of Incorporation (Exhibit 3(ii) to the
Company's Annual Report on Form 10-KSB for the year ended
December 31, 1995, File Number 0-15476, incorporated herein by
reference).
4 Instruments defining the rights of security holders, including
debentures.
(a) Promissory Notes to Directors and Other Investors (Exhibit 10
to the Company's Quarterly Report on Form 10-QSB for the period
ended September 30, 1996, File Number 0-15476, incorporated
herein by reference).
(b) Financing and Shareholder Agreement (Exhibit 10 to the
Company's Current Report on Form 8-K dated February 5, 1997,
file number 0-15746, incorporated herein by reference).
(c) 9 1/2% Convertible Note issued to directors and other investors
and related Class Z1 and Class Z2 Warrants (Exhibit to the
Company's Annual Report on Form 10-KSB for the year ended
December 31, 1997, File Number 0-15476, incorporated herein by
Reference).
21 List of Subsidiaries (Exhibit 21 to the Company's Annual Report
on Form 10 KSB for the year ended December 31, 1996, File No.
0-15476, incorporated herein by reference.)
27 Financial Data Schedule
(b) Reports on Form 8-K
None
10
<PAGE> 11
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: April 12, 1999 Zaxis International Inc.
By:/S/ CONALY BEDELL
-----------------
Conaly Wm. Bedell, President
and Chief Executive Officer
In accordance with the Exchange Act, this report has been signed below by the
following persons on behalf of the Registrant and in the capacities and on the
date indicated.
Signatures Title Date
- ---------- ----- ----
- -------------------------- Director, Chairman of the Board April 12, 1999
Conaly Bedell
Director April 14, 1999
- --------------------------
Leonard Duval
Director April 15, 1999
- --------------------------
Craig Jones*
Director April 13, 1999
- --------------------------
Alan Scott
Director April 15, 1999
- --------------------------
Calvin D. Wible*
Accounting Department Manager April 12, 1999
- --------------------------
Sharon Killinger
* Pursuant to Power of Attorney.
11
<PAGE> 12
Report of Independent Auditors
The Board of Directors and Stockholders
Zaxis International Inc.
We have audited the accompanying consolidated balance sheets of Zaxis
International Inc. and Subsidiary as of December 31, 1998 and 1997, and the
related consolidated statements of operations, stockholders' deficiency and cash
flows for the years then ended. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated financial position of Zaxis
International Inc. and Subsidiary at December 31, 1998 and 1997, and the
consolidated results of their operations and their cash flows for the years then
ended in conformity with generally accepted accounting principles.
The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. As discussed in Note 1 to the
financial statements, the Company has suffered recurring losses from operations,
has liabilities in excess of total assets and has a working capital deficiency.
These conditions raise substantial doubt about the Company's ability to continue
as a going concern. Management's plans in regard to these matters are also
described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
/S/ERNST & YOUNG LLP
Cleveland, Ohio
April 8, 1999
12
<PAGE> 13
<TABLE>
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
<CAPTION>
ASSETS
------
DECEMBER 31, DECEMBER 31,
1998 1997
------------ ------------
<S> <C> <C>
CURRENT ASSETS:
Cash $ 49,327 $ 81,410
Accounts receivable, net 13,904 39,071
Inventory 64,738 76,320
Prepaid expenses and other 29,671 16,908
----------- -----------
Total current assets 157,639 213,709
PROPERTY AND EQUIPMENT:
Machinery and equipment 360,082 353,461
Office equipment 190,064 189,117
Leasehold improvements 86,992 86,992
----------- -----------
637,139 629,570
Less accumulated depreciation 400,731 289,610
----------- -----------
236,407 339,960
OTHER ASSETS:
Patent costs 37,910 41,853
Organization costs 395 2,764
----------- -----------
38,304 44,617
----------- -----------
TOTAL ASSETS $ 432,351 $ 598,285
=========== ===========
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
----------------------------------------
CURRENT LIABILITIES:
Current portion of lease obligations $ 10,906 $ 10,238
Notes payable to directors 784,895 92,020
Notes payable 475,264 118,000
Accounts payable 476,962 430,513
Accrued expenses 449,341 222,327
----------- -----------
Total current liabilities 2,197,367 873,098
LONG TERM LIABILITIES:
Capitalized lease obligations 28,705 38,763
Notes payable 130,000 271,289
Notes payable to directors 684,012 777,590
----------- -----------
Total long term liabilities 842,717 1,087,642
STOCKHOLDERS' DEFICIENCY:
Common stock 58,112 57,450
$.01 par value, 12,000,000 shares authorized,
5,811,216 and 5,744,991 shares issued and outstanding
Additional paid-in capital 5,984,885 5,945,774
Accumulated deficit (8,650,731) (7,365,678)
----------- -----------
Total stockholders' deficiency (2,607,734) (1,362,455)
----------- -----------
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY $ 432,351 $ 598,285
=========== ===========
</TABLE>
See notes to consolidated financial statements
13
<PAGE> 14
<TABLE>
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
<CAPTION>
YEARS ENDED
DECEMBER 31
----------------------------
1998 1997
----------- -----------
<S> <C> <C>
Net sales $ 188,732 $ 274,539
Cost of goods sold 392,033 686,892
Selling, general and administrative expenses 923,715 815,866
----------- -----------
Loss from operations (1,127,016) (1,228,219)
Other income (expense):
Interest expense (164,859) (94,430)
Other, net 6,822 2,384
----------- -----------
Total other income (expense) (158,037) (92,046)
----------- -----------
Net loss $(1,285,053) $(1,320,265)
=========== ===========
Net loss per common share - basic and diluted $ (0.22) $ (0.23)
=========== ===========
Weighted average number of shares outstanding - basic and diluted 5,764,366 5,619,814
=========== ===========
</TABLE>
See notes to consolidated financial statements.
14
<PAGE> 15
<TABLE>
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIENCY
<CAPTION>
COMMON STOCK
---------------------- ADDITIONAL
NUMBER OF STATED OR PAID-IN DEFERRED ACCUMULATED
SHARES PAR VALUE CAPITAL COMPENSATION DEFICIT
--------- --------- ---------- ------------ -----------
<S> <C> <C> <C> <C> <C>
Balance at December 31, 1996 5,438,019 $54,380 $5,404,540 $(30,868) $(6,045,413)
Sales of shares 108,918 1,089 177,932
Shares issued on conversion of notes 198,054 1,981 388,554
Amortization of deferred compensation 5,616
Forfeiture of unvested stock grants (25,252) 25,252
Net loss - 1997 (1,320,265)
--------- ------- ---------- -------- -----------
Balance at December 31, 1997 5,744,991 $57,450 $5,945,774 $ -- $(7,365,678)
Shares issued for compensation 66,225 662 39,111
Net loss - 1998 (1,285,053)
--------- ------- ---------- -------- -----------
Balance at December 31, 1998 5,811,216 $58,112 $5,984,885 $ -- $(8,650,731)
========= ======= ========== ======== ===========
</TABLE>
See notes to consolidated financial statements.
15
<PAGE> 16
<TABLE>
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS
<CAPTION>
TWELVE MONTHS ENDED
DECEMBER 31,
-----------------------------
1998 1997
----------- ------------
<S> <C> <C>
OPERATING ACTIVITIES:
Net loss $(1,285,053) $(1,320,265)
Adjustments to reconcile net loss to cash
used in operating activities:
Depreciation and amortization 119,678 112,523
Compensation due to stock option grants 39,773 5,616
Changes in operating assets and liabilities:
Restricted cash -- 100,000
Accounts receivable 25,167 3,397
Inventory and prepaid expenses (1,181) 89,950
Accounts payable and accrued expenses 273,463 16,770
----------- -----------
Cash used in operating activities (828,153) (992,009)
INVESTING ACTIVITIES:
Purchase of property and equipment (7,569) (18,092)
Patent cost expenditures (2,243) (13,742)
----------- -----------
Cash used in investing activities (9,812) (31,834)
FINANCING ACTIVITIES:
Proceeds from sales of common stock -- 170,000
Payments on notes payable (16,045)
Proceeds from notes payable and bank loans payable 831,317 944,969
Payments on capital lease obligations (9,390) (10,806)
----------- -----------
Cash provided by financing activities 805,882 1,104,163
----------- -----------
Increase (Decrease) in cash (32,083) 80,320
Cash at beginning of period 81,410 1,090
----------- -----------
Cash at end of period $ 49,327 $ 81,410
=========== ===========
Non cash transactions:
Capital lease $ 39,611 $ 57,867
Notes converted to stock -- 390,535
Supplemental Information
Interest paid on notes $ 21,483 $ 17,574
</TABLE>
See notes to consolidated financial statements.
16
<PAGE> 17
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. NATURE OF OPERATIONS AND LIQUIDITY
Zaxis International, Inc. and subsidiary manufactures and sells products for use
in electrophoresis, an electrochemical process used to analyze genetic material
and its components such as proteins and DNA. The products include testing media,
primarily in the form of precast polyachrylamide gel cassettes, electrophoresis
chambers, chemical compounds and reagents. The Company also sells equipment
manufactured to its specifications for use in performing electrophoresis, such
as power supplies, and in the analysis and quantification of electrophoresis
results, including computer systems and automated scanners. The Company sells
its products directly to institutions operating research laboratories and to
distributors who market the Company's products under the Zaxis name or their
private labels. The Company's blood serum lipoprotein assay system is marketed
directly to research laboratories. The system was granted clearance to be
marketed for clinical use by the Food and Drug Administration in September 1996.
The Company was primarily engaged in research and development activities from
1989 until 1994. In 1994, the Company moved into its present office and
manufacturing facilities and began selling certain products, finalizing product
planning and design, developing its computerized manufacturing process, and
setting marketing and distribution plans. In 1995, a private placement of units
consisting of common stock and two series of common stock warrants was
completed, resulting in net proceeds of $1,424,000. The proceeds were used to
complete the projects started in 1994, continue research activities and provide
funds during the startup of product manufacturing and marketing. During 1996,
the Company obtained financing totaling $1,955,000 from sales of common stock
and notes which was primarily used to fund operations as the Company sought to
establish marketing arrangements for its products.
In 1997, the Company entered into a Financing and Shareholder Agreement with MML
Management Limited, an Australia-based investment firm ("MML"). MML and
affiliated entities provided $857,590 in funding to the Company, of which
$90,000 was for stock purchases and the remainder of which was convertible debt.
In 1998, the Company received funds of $601,317 from MML and affiliated
entities, which was convertible debt. The Company also received funds of
$230,000 in 9 1/2% convertible debt from private investors.
Zaxis incurred losses of $1,285,053 in 1998 and $1,320,000 in 1997. The Company
does not expect to generate sufficient sales volume with its existing customer
base to support the cost of operations during the 1999-year and will continue to
be reliant on investor funding during this year. The Company is seeing initial
positive results from its efforts to strengthen its customer base, which in 1998
was reflected in pursuit of additional private label distributors for the
Company's protein electrophoresis products, completion of development and
prototype testing of its precast DNA sequencing product and sales of its LFS
clinical device to increase repeat demand for the LFS gel. An important
private-label contract was negotiated during 1998 and was formally signed on
March 5, 1999. First sales under this agreement, referenced in 10-KSB Item1,
Business Development, Business of the Issuer section, are expected to occur in
the second quarter of 1999. Initial end-user sales of the DNA gel on a
test-quantity basis were delivered in January 1999. The Company has forecast
that it could see product delivery ramp-ups build to where the Company could
become cash flow positive in about five quarters after the last of the necessary
contracts are signed.
MML Management Ltd. continues to be committed to the success of the Company. A
major shareholder, with an MML affiliation, made a substantial debt investment
in the Company in 1998. Currently the Company is negotiating for long-term
investment infusions through MML affiliations and through sources in Canada
introduced to the Company by MML. Northeast Ohio financial interests continued
during 1998 and the first quarter of 1999 to provide on-going financial
investment support for the Company. There can be no assurance that the Company
will continue to receive investor funding nor that the Company will be able to
strengthen its
17
<PAGE> 18
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
customer base sufficiently to generate the sales volume required to meet or
exceed the costs of operations. These conditions continue to focus doubt about
the Company's ability to continue as a going concern. No adjustments to the
amounts or classification of assets and liabilities, which could result from the
outcome of this uncertainty, are reflected in the financial statements.
2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The financial statements present the consolidated financial position and results
of operations of Zaxis International Inc. (International) and Zaxis Inc. (Zaxis
or the Company), its wholly owned subsidiary.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
INVENTORY
Inventories are stated at the lower of cost, determined using the first-in,
first-out method, or market value.
PROPERTY AND EQUIPMENT
Property and equipment are stated on the basis of cost. Depreciation is computed
using the straight-line method over the estimated useful lives of the assets.
Classes of property and equipment and related useful lives are as follows:
<TABLE>
<CAPTION>
Estimated
Asset Useful Life
------------------------ -----------
<S> <C>
Leasehold improvements 5
Machinery and equipment 5 - 10
Office equipment 5 - 7
</TABLE>
Depreciation expense including amortization of capitalized leases charged to
operations was $111,385 and $105,140 for 1998 and 1997, respectively.
ASSET IMPAIRMENT
The Company's policy is to review long-lived assets for impairment whenever
events or changes in circumstances indicate that the carrying amount of these
assets may not be recoverable, in which case the asset generally would be
written down to fair value.
INTANGIBLES
Patent costs are amortized over the life of the patents. Amortization expense
was $6,186 and $5,013 for 1998
18
<PAGE> 19
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
and 1997, respectively, and accumulated amortization was $17,597 and $11,411 at
December 31, 1998 and 1997, respectively.
Organization costs are amortized over five years. Accumulated amortization was
$11,450 and $9,081at December 31, 1998 and 1997, respectively.
INCOME TAXES
The Company accounts for income taxes using the liability method of accounting.
Under the liablility method, deferred tax assets and liabilities are determined
based upon differences between financial reporting and tax bases of assets and
liabilities and are measured using the currently enacted tax rates.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying values of cash, accounts receivable and accounts payable are a
reasonable estimate of their fair value due to the short-term nature of these
instruments. Notes payable to directors and others do not have a ready market,
and cost is assumed to approximate fair value. The aggregate carrying value of
these notes is $2,074,171 at December 31, 1998, with interest rates ranging from
9.25% to 10% and maturity dates ranging from March 5, 1999 through December 17,
2000.
RESEARCH AND DEVELOPMENT COSTS
Research and development costs are expensed as incurred. Research and
development costs were approximately $241,777 and $127,000 for 1998 and 1997,
respectively. The large increase is due to re-design of the protein gel and the
completion of research on the DNA gel.
STOCK COMPENSATION
As permitted by Statement of Financial Accounting Standards No. 123, "Accounting
for Stock-Based Compensation," the Company has elected to use the method of
accounting prescribed by Accounting Principles Board Opinion No. 25, "Accounting
for Stock Issued to Employees." This method results in no compensation cost
being recognized. The pro forma effect of using the alternative method under
SFAS 123 results in a pro forma net loss that is not materially different from
amounts reported.
ADVERTISING COSTS
Advertising costs are expensed when incurred. Advertising expense amounted to
$3,049 in 1998 and $4,601 in 1997.
NEW ACCOUNTING PRONOUNCEMENTS
In June 1997, the FASB issued Statement 130, "Reporting Comprehensive Income,"
which establishes standards for the reporting and display of comprehensive
income and its components in a full set of financial statements. The Company has
adopted the new standard in 1998, and it had no effect on the financial
statements.
19
<PAGE> 20
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
In June 1998, the FASB issued Statement 133, "Accounting for Derivative
Instruments and Hedging Activities," which is required to be adopted in the year
2000. Because the Company does not currently utilize derivative financial
instruments, the adoption of the new statement is not expected to effect the
Company's financial statements.
RECLASSIFICATIONS
Certain amounts that were reported in the 1997 financial statements have been
reclassified to conform to the 1998 presentation.
3. BANK LOAN AND NOTES PAYABLE
Notes payable to directors of $1,468,907 at December 31, 1998 are due at various
dates from March 5, 1999 through December 17, 2000 and bear interest at rates
from 9.25% to 10%.
Notes payable to others of $605,264 at December 31, 1998 are due $123,975 on
demand and $481,289 at various dates from December 1, 1999 through December 17,
2000 and bear interest at rates from 9.25% to 10%.
Holders of notes payable were granted warrants to purchase 452,667 shares of
common stock at $1.00 to $3.00 per share for up to three years from the dates of
issuance. Certain of the notes payable include terms which permit the holder to
be repaid in shares of common stock by exercising the warrants. If the holder so
elects, the Company will grant additional common stock warrants for the same
exercise price in an amount equivalent to 50% of the warrants exercised. No
value has been assigned to the warrants.
Notes payable totaling $1,860,196 are convertible into common stock at prices
ranging from $2.00 to $3.24. If converted, the Company will issue warrants at
prices ranging from $2.50 to $4.00 equal to the number of shares issued through
the conversion.
At December 31, 1998, the Company was delinquent on principal payments of
$58,000 and interest payments of $123,158.
Future maturities of long term debt assuming the notes are not converted prior
to maturity are as follows:
<TABLE>
<S> <C>
1999 1,260,159
2000 814,012
----------
Total $2,014,171
</TABLE>
4. DEFINED CONTRIBUTION PLAN
The Company maintains a 401(k) plan for substantially all employees. Company
contributions are at the discretion of management. There were no Company
contributions under the plan in 1998 or 1997.
20
<PAGE> 21
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
5. LEASE OBLIGATIONS
The Company has equipment under capital leases as follows:
<TABLE>
<CAPTION>
December 31,
---------------------
1998 1997
------- -------
<S> <C> <C>
Cost $75,801 $75,801
Less accumulated amortization 26,530 11,370
------- -------
$49,271 $64,431
======= =======
</TABLE>
The Company rented a building for its office, research and development and
manufacturing under a sub-lease agreement through October 1998. Starting in
November 1998, the Company rents the same building under a five-year prime
lease. Rent expense was $105,292 in 1998 and $112,700 in 1997.
<TABLE>
<S> <C> <C>
Rent obligations: 1999 $110,042
2000 114,792
2001 119,542
2002 124,292
2003 106,875
</TABLE>
6. CAPITAL STOCK TRANSACTIONS
During 1998, the Company issued 4,034 shares of common stock at price of $.6875
for directors fees. The Company also issued 12,191 and 50,000 shares of common
stock at price of $.9843 and $.50, respectfully for compensation.
During 1997, the Company sold 82,500 shares of common stock at price of $2.00
per share in a private offering. Notes payable plus interest were converted to
197,581 shares of stock at prices ranging from $2.00 to $3.24 per share
depending on the terms of the note. These investors were issued 292,419 warrants
to purchase stock at $3.00 per share which expired on March 30, 1999.
7. INCOME TAXES
A reconciliation of income taxes computed at the U.S. federal statutory rate to
the provision for income taxes is as follows:
<TABLE>
<CAPTION>
1998 1997
--------- ---------
<S> <C> <C>
Tax benefit at statutory rate $(437,000) $(471,640)
Increase in valuation allowance on deferred tax asset 437,000 471,640
--------- ---------
Provision for income taxes $ -- $ --
========= =========
</TABLE>
Deferred income taxes are provided to reflect the tax effects of temporary
differences in the recognition of revenue and expense for tax and reporting
purposes. Significant components of deferred tax assets at December 31, 1998 and
1997 are as follows:
21
<PAGE> 22
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
<TABLE>
<CAPTION>
1998 1997
----------- -----------
<S> <C> <C>
Deferred tax assets:
Net operating loss carryforward $ 2,536,640 $ 2,106,640
Other, net 39,000 32,000
----------- -----------
2,571,640 2,138,640
Valuation allowance (2,575,640) (2,138,640)
----------- -----------
Net deferred tax assets $ -- $ --
=========== ===========
</TABLE>
For Federal income tax purposes, net operating loss carryovers total $7,460,000,
which may be subject to significant change in ownership limitations, that, if
not utilized, will expire between 2004 and 2013.
8. STOCK OPTIONS AND WARRANTS:
As of December 31, 1998 the following warrants are outstanding:
60,000 warrants exercisable at $1.50 related to debt issuances expiring at
various dates from May 5, 1999 through May 21, 1999.
208,432 warrants exercisable at $3.00 related to debt issuances expiring at
various dates from June 2, 1999 through October 28, 2000.
491,600 Class B warrants exercisable at $3.50 related to previous stock
purchases expiring on September 30, 1999.
367,419 Class C warrants exercisable at $3.00 related to prior year stock
issuances and debt issuances expiring on March 30, 1999.
285,000 Class C Series 2 warrants exercisable at $1.00 expiring April 30, 1999.
2,000 Class Y warrants exercisable at $.9687 expiring August 11, 2000.
There are 3,331,114 shares of common stock reserved for warrants and stock
options.
International has a long term incentive plan under which options to purchase
405,000 shares of common stock may be granted at the fair market value on the
date of grant in the form of incentive or non-qualified stock options. In
addition, the Company has a Non-Employee Director's Stock Option plan under
which options to purchase up to 100,000 shares may be granted at fair market
value at the date of grant.
During 1998, 100,250 (98,660 in 1997) options were granted with exercise prices
between $.55 and $.9687 ($1.44 and $5.50 in 1997) and expire three, five or ten
years from the date of grant. These options were exercisable upon grant. At
December 31, 1998, 302,378 (202,728 at December 31, 1997) options were
outstanding with a weighted average exercise price of $2.07 ($2.39 at December
31, 1997). No options were exercised during 1998 or 1997.
22
<PAGE> 23
ZAXIS INTERNATIONAL INC. AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
9. MAJOR CUSTOMERS
Six customers accounted for 55% of sales in 1998 and two customers accounted for
58% of sales in 1997. Since the Company will not be able to cover its operating
costs unless the customer base is increased, the loss of any of the major
customers could have a material adverse effect on the Company.
23
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> DEC-31-1998
<CASH> 49,327
<SECURITIES> 0
<RECEIVABLES> 13,904
<ALLOWANCES> 0
<INVENTORY> 64,738
<CURRENT-ASSETS> 157,639
<PP&E> 637,139
<DEPRECIATION> 400,731
<TOTAL-ASSETS> 432,351
<CURRENT-LIABILITIES> 2,197,367
<BONDS> 0
0
0
<COMMON> 68,112
<OTHER-SE> 0
<TOTAL-LIABILITY-AND-EQUITY> 432,351
<SALES> 188,732
<TOTAL-REVENUES> 188,732
<CGS> 392,033
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (164,859)
<INCOME-PRETAX> 0
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,285,053)
<EPS-PRIMARY> (0.22)
<EPS-DILUTED> 0
</TABLE>
